Circulating Mesenchymal Stromal Cells in Patients with Infantile Hemangioma: Evaluation of Their Functional Capacity and Gene Expression Profile.

Autor: Abbà C; General Medicine 2-Center for Systemic Amyloidosis and High-Complexity Diseases, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy., Croce S; Immunology and Transplantation Laboratory, Cell Factory, Pediatric Haematology Oncology, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy., Valsecchi C; Immunology and Transplantation Laboratory, Cell Factory, Pediatric Haematology Oncology, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy., Lenta E; Immunology and Transplantation Laboratory, Cell Factory, Pediatric Haematology Oncology, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy., Campanelli R; Center for the Study of Myelofibrosis, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy., Codazzi AC; Pediatric Cardiology, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy., Brazzelli V; Institute of Dermatology, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy., Carolei A; Center for the Study of Myelofibrosis, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy., Catarsi P; Center for the Study of Myelofibrosis, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy., Acquafredda G; Immunology and Transplantation Laboratory, Cell Factory, Pediatric Haematology Oncology, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy., Apicella A; Pediatric Cardiology, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy., Caliogna L; Orthopedics and Traumatology Clinic, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy., Berni M; Orthopedics and Traumatology Clinic, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy., Mannarino S; Pediatric Cardiology Unit, V. Buzzi Children's Hospital, 20154 Milan, Italy., Avanzini MA; Immunology and Transplantation Laboratory, Cell Factory, Pediatric Haematology Oncology, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy., Rosti V; Center for the Study of Myelofibrosis, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy., Massa M; General Medicine 2-Center for Systemic Amyloidosis and High-Complexity Diseases, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy.
Jazyk: angličtina
Zdroj: Cells [Cells] 2024 Jan 29; Vol. 13 (3). Date of Electronic Publication: 2024 Jan 29.
DOI: 10.3390/cells13030254
Abstrakt: We previously published that in patients with infantile hemangioma (IH) at the onset (T0) colony forming unit-fibroblasts (CFU-Fs) are present in in vitro cultures from PB. Herein, we characterize these CFU-Fs and investigate their potential role in IH pathogenesis, before and after propranolol therapy. The CFU-F phenotype (by flow cytometry), their differentiation capacity and ability to support angiogenesis (by in vitro cultures) and their gene expression (by RT-PCR) were evaluated. We found that CFU-Fs are actual circulating MSCs (cMSCs). In patients at T0, cMSCs had reduced adipogenic potential, supported the formation of tube-like structures in vitro and showed either inflammatory (IL1β and ESM1 ) or angiogenic ( F3 ) gene expression higher than that of cMSCs from CTRLs. In patients receiving one-year propranolol therapy, the cMSC differentiation in adipocytes improved, while their support in in vitro tube-like formation was lost; no difference was found between patient and CTRL cMSC gene expressions. In conclusion, in patients with IH at T0 the cMSC reduced adipogenic potential, their support in angiogenic activity and the inflammatory/angiogenic gene expression may fuel the tumor growth. One-year propranolol therapy modifies this picture, suggesting cMSCs as one of the drug targets.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje